.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG07_Begelomab.Begelomab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG07_Begelomab.Begelomab| name: | Begelomab | |
| ATC code: | L04AG07 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 4 | mg |
| volume of distribution: | 0.06 | L |
| clearance: | 0.2 | L/day |
| other parameters in model implementation | ||
Begelomab is a monoclonal antibody directed against CD26, developed for immunosuppression in transplantation, particularly in steroid-refractory acute graft-versus-host disease (aGVHD). It has received orphan drug designation but is not widely approved or in routine use.
No published pharmacokinetic studies are available for begelomab in humans in the scientific literature as of June 2024. Estimated PK parameters for monoclonal antibodies of similar class are provided.